HemoRel A (anti - hemophilic factor) / Reliance Life Sci - LARVOL DELTA

Lurbinectedin Synergizes with Selinexor by Inhibiting DNA Damage Repair and Enhancing Immune Cell Infiltration in Neuroendocrine Lung Tumors (IASLC-WCLC 2024) - "Conclusions : These findings suggest that selinexor combined with lurbinectedin is a promising therapeutic combination in both SCLC and LCNEC. Our study offers a strong preclinical rational for investigating this strategy in patients with lung NECs who fail chemotherapy regimens."

Immune cell • IO biomarker • Endocrine Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • CHEK1 • CHEK2 • IFNG • RB1 • RBL2 • STING • TP53 • XPO1

Lurbinectedin Synergizes with Selinexor by Inhibiting DNA Damage Repair and Enhancing Immune Cell Infiltration in Neuroendocrine Lung Tumors (IASLC-WCLC 2024) - "Conclusions : These findings suggest that selinexor combined with lurbinectedin is a promising therapeutic combination in both SCLC and LCNEC. Our study offers a strong preclinical rational for investigating this strategy in patients with lung NECs who fail chemotherapy regimens."

Immune cell • IO biomarker • Endocrine Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • CHEK1 • CHEK2 • IFNG • RB1 • RBL2 • STING • TP53 • XPO1

A prospective, multicenter, clinical Study to evaluate the Safety, Pharmacokinetics, and Efficacy of Bleed Outcomes, with HemoRel-A® in severe Hemophilia A Patients. (PubMed, J Assoc Physicians India) - "HemoRel-A® was established to be efficacious and safe in the treatment of acute bleeding events in subjects with severe hemophilia A."

Journal • PK/PD data • Hematological Disorders • Hemophilia • Rare Diseases

Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy. (PubMed, Cancer Res) - "The small molecule exportin-1 inhibitor selinexor in combination with cisplatin or irinotecan dramatically inhibited tumor growth in chemonaïve and chemorelapsed SCLC patient-derived xenografts, respectively. Together these data identify exportin-1 as a promising therapeutic target in SCLC with the potential to markedly augment the efficacy of cytotoxic agents commonly used in treating this disease."

Clinical • Journal • CNS Disorders • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • XPO1

Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples. (PubMed, Front Med (Lausanne)) - "Rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate directed against Delta-like protein 3 (DLL3), is under development for patients with small cell lung cancer (SCLC). Unlike in chemonaive samples, a high DLL3 expression in chemorelapsed samples indicated a trend for a more favorable prognosis. Our results highlight the importance to investigate DLL3 in latest chemorelapsed SCLC tumor tissue."

Journal • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3

[VIRTUAL] CRISPR Screen Reveals XPO1 as a Therapeutic Target Strongly Sensitizing to First and Second Line Therapy in Small Cell Lung Cancer (IASLC-WCLC 2021) - "Conclusion Exportin 1 is highly expressed in SCLC tumors, independent of their subtype, and its inhibition enhances sensitivity to the chemotherapeutic drugs used in first line and second line treatment of SCLC tumors. Our results provide preclinical rationale for the combination of selinexor with cisplatin or with irinotecan as first or second line treatment, respectively, of SCLC."

Clinical • IO biomarker • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • XPO1